Welcome to our dedicated page for Catalent news (Ticker: CTLT), a resource for investors and traders seeking the latest updates and insights on Catalent stock.
Catalent Inc. (CTLT) operates in the pharmaceutical contract development and manufacturing sector, making its news particularly relevant for investors tracking the drug development services industry. As a CDMO serving pharmaceutical and biotechnology clients globally, Catalent's announcements often reflect broader trends in pharmaceutical outsourcing, biologics manufacturing, and drug delivery innovation.
News coverage for Catalent typically includes developments related to manufacturing capacity expansions, client partnerships, and acquisitions in the CDMO space. The company's position as a service provider to the pharmaceutical industry means its business developments often correlate with trends in drug pipelines and the broader shift toward outsourced manufacturing.
Investors and analysts monitoring Catalent look for updates on facility investments, particularly in high-growth areas like cell and gene therapy manufacturing. Contract announcements and capacity utilization discussions provide insight into demand for pharmaceutical outsourcing services. Leadership changes and governance updates, such as board appointments, signal strategic direction for the company.
Track Catalent news on Stock Titan to follow developments in this pharmaceutical services company. Bookmark this page for updates on manufacturing operations, partnership announcements, and industry developments affecting the contract manufacturing sector.
Catalent, a global leader in drug development and supply, announced the approval of its acquisition by Novo Holdings. At a Special Meeting, Catalent stockholders voted in favor of the Merger with 99.2% approval. Novo Holdings will acquire all outstanding shares of Catalent for $63.50 per share in cash. Catalent's President and CEO, Alessandro Maselli, expressed gratitude for the stockholders' support and confidence in Catalent's future. The transaction, anticipated to close by the end of 2024, is subject to regulatory approvals and customary closing conditions. The transaction is not contingent on financing.
Catalent, Inc. reported third quarter fiscal 2024 results with a net revenue increase of 4% compared to Q3'23, excluding COVID-related revenue. The net loss decreased from $(227) million in Q3'23 to $(101) million in Q3'24. Adjusted EBITDA increased by 55% compared to Q3'23. Catalent's pending transaction with Novo Holdings is expected to close by the end of 2024.
FAQ
What is the current stock price of Catalent (CTLT)?
What is the market cap of Catalent (CTLT)?
